Up to the early 16th century, essentially medical diagnostics was limited to uroscopy – the observation of a urine sample in a uroscopy flask with a candle providing light. In a visual examination the doctor would determine the colour of the urine as well as cloudiness and precipitates, followed by a smell and taste test. The information he gathered provided the basis of his diagnosis. 100…
A team of scientists and engineers at The University of Texas at Austin has invented a powerful tool that rapidly and accurately identifies cancerous tissue during surgery, delivering results in about 10 seconds—more than 150 times as fast as existing technology.
While IA’s (Immunoassay) has been the most used technic for clinical analysis, the shift to LC-MS / MS is constantly increasing for several type of analysis like immunosuppressant, vitamin D or steroids panel, but also for several new assays including anti-coagulants, antibiotics, plasma renin activity, etc. The change from Immunoassay to LC-MS / MS could have been faster if sample…
Cancer biomarker testing represents an important element of the clinical biochemistry service, yet progress in this area in the last two decades has been slow.
Combining the physical separation power of liquid chromatography with the mass analysis capability of mass spectrometry – i.e. liquid chromatography tandem mass spectrometry (LC-MS/MS) – enables accurate, sensitive and selective separation, detection and identification of molecules in complex mixtures such as blood, serum and urine.
SCIEX Diagnostics, the in vitro diagnostics division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced the first and only FDA-cleared (via the de novo pathway) LC-MS based Vitamin D assay kit, the Vitamin D 200M Assay, exclusively for the SCIEX Topaz System. The Topaz System is a fully integrated LC-MS platform driven by ClearCore MD, the new and intuitive…
SCIEX, a global leader in life science analytical technologies, hosted the 7th Berliner LC-MS/ MS Symposium, which took place from 13th-15th March 2017 at the Estrel Hotel in Berlin. The Symposium included a diverse programme of talks from internationally respected researchers and analytical scientists. These covered the latest mass spectrometry developments in pharmaceutical, omics, precision…
About six years ago, liquid biopsy appeared on the diagnostic lab stage. Last December, a seminar offered by Agena Bioscience in Frankfurt, Germany, was set to explore the enormous potential of this new technique for oncology.
Scientists at a UK university are using the power of mass spectrometry to research critical processes in human prostate cancer.
Pathology does not appear to have much in common with satellites, but the concept that satellites combine spatial resolution and image quality will be the future of disease diagnosis, according to researchers.
From barcode scanning, RFID and medical machine vision to chart recorders, thermal printers and spectroscopy products, JADAK designs and manufactures embedded solutions that help customers solve unique inspection, tracking, scanning and documenting challenges.
Cancer patients today can benefit from much better drugs providing treatments tailor-made to specific mutations. However, broad application is still hampered by a considerable bottleneck: fast, reliable, and cost-effective diagnosis. Agena's MassARRAY platform is addressing this bottleneck with an elegant new solution.
Since several years, LC-MS/MS technology is making an important breakthrough in the field of clinical research. The progress of tandem MS or MS/MS in that field is mainly due to its ability for high sensitivity detection, high selectivity, as well as possibilities of multiplexing compounds in one analysis without the risk of cross reactions inherent to immuno-assay tests.
An international public-private research consortium has identified and validated a cellular role of a primary Parkinson’s disease drug target, the LRRK2 kinase. This important finding illuminates a novel route for therapeutic development and intervention testing for Parkinson’s, the second most common neurodegenerative disease after Alzheimer’s.
SCIEX announced today that Aarhus University Hospital in Denmark has invested in SCIEX QTRAP 6500 technology to develop novel mass spectrometry-based assays for clinical research laboratories. Scientists at the hospital’s Department of Clinical Biochemistry are using the QTRAP 6500 LC-MS/MS system for advanced clinical research, due to its exceptional sensitivity and selectivity, which are…
During the past 15 years, liquid chromatography tandem mass spectrometry (LC-MS/MS) has evolved into a vital technology used to perform routine tests in many clinical laboratories. Historically, LC-MS/MS had been used primarily by research, pharmaceutical, or commercial laboratories; however, advances in the technology, decreasing costs for basic systems, intelligible software, an increased…
With its previous LCMS-8030, LCMS-8040 and LCMS-8050 triple-quadrupole systems, Shimadzu has set leading standards in terms of speed, sensitivity and functional design. With the introduction of the new LCMS-8060 (Figure 1), the success story of the LCMS-triple-quadrupole family reaches another milestone.
This year’s German medical diagnostics manufacturers association (Verband der deutschen Diagnostica-Hersteller = VDGH) congress, focused on diabetes. The panel discussion that closed the evening session revealed unanimous support for the adoption of a German national diabetes plan. Report: Bettina Döbereiner
Bringing liquid chromatography and tandem mass spectrometry (LC-MS/MS) testing into clinical laboratories has been a slow process but continues to show promise to help improve patient care. The medical device industry is on the edge of fundamental breakthroughs that can help drive the adoption into more mainstream clinical laboratories. We recently sat down with Dr Bori Shushan, Mass Spectrometry…
Double-digit growth in Asia-Pacific and emerging markets to offset stagnation in US and Europe.
908 Devices has good reason to be based in Boston’s Innovation District. A start-up founded in 2012, the company plans to disrupt the field of chemical analysis with what Vice President Chris Petty calls ‘ridiculously small, and elegantly simple’ mass spectrometry technology.
Mass spectrometry has been applied in advanced clinical research and drug discovery and development. Continual innovations have created capabilities to address complex analytical challenges qualitatively and quantitatively with unparalleled speed, sensitivity and accuracy
‘Mass spectrometry has developed into a successful routine procedure,’ according to Dr Christoph Seger (Univ. Doz.), technical head of the Mass Spectrometry and Chromatography division at the Central Institute of Medical and Chemical Laboratory Diagnostics, Innsbruck University Hospital, Austria.
Mass spectrometry is pushing the boundaries of clinical pathology. Keep up-to-date with the latest research news, developments, and background information on the technique.